![Quiver Logo](/static/img/logo-icon.png)
![RNAZ logo](https://quiver-logos.s3.us-east-2.amazonaws.com/rnaz.png)
TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RNAZ Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of RNAZ by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RNAZ's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to RNAZ
Recent picks made for RNAZ stock on CNBC
ETFs with the largest estimated holdings in RNAZ
Flights by private jets registered to RNAZ
![Quiver Logo](/static/img/logo-icon.png)